Exemestane for breast-cancer prevention in postmenopausal women.

By P. Goss, J. Ingle, J. Alés‐Martínez, A. Cheung, R. Chlebowski, J. Wactawski‐Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin and 10 more. New England Journal of Medicine, 2011

910 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics

View Paper: https://www.semanticscholar.org/paper/f81200ba2a0d9aed1480d1ed908342532438884c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Jianmin Jiang
2. W. Shi
3. Yi-Sheng Sun
4. Zhi-yong Zhu
5. P. Yao
6. Hanping Zhu
7. Hangjing Lu
8. Fang Xu

Citations in the corpus

• Risk Factors and Preventions of Breast Cancer (2017, background): “Many trials such as the Italian Tamoxifen Anastrozole (ITA) trial, Intergroup Exemestane Study (IES), Austrian Breast and Colorectal Cancer Study Group (ABCSG-8), and the Breast International Group (BIG) 1-98 study have showed that in the adjuvant setting, AIs are more potent than TAM in reducing th”